NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 23 pharmaceutical companies such as HOSPIRA, TEVA PHARMS USA, XELLIA PHARMS APS and others. It is marketed under 4 brand names, including DAPTOMYCIN, CUBICIN RF, DAPZURA RT and others. Available in 6 different strengths, such as 500MG/VIAL, 350MG/VIAL, 700MG/100ML (7MG/ML) and others, and administered through 2 routes including POWDER;INTRAVENOUS, SOLUTION;INTRAVENOUS.
API availability: Loading API feasibility...
Licensing: 23 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"66719","ingredient":"DAPTOMYCIN","trade_name":"CUBICIN","family_id":"7795b5cfe4d94dee8e1f","publication_number":"US8003673B2","cleaned_patent_number":"8003673","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-09-04","publication_date":"2011-08-23","legal_status":"Granted"} | US8003673B2 | 23 Aug, 2011 | Granted | 04 Sep, 2028 | |
| {"application_id":"66724","ingredient":"DAPTOMYCIN","trade_name":"CUBICIN RF","family_id":"77e3df70c1664907b73c","publication_number":"US9138456B2","cleaned_patent_number":"9138456","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-11-23","publication_date":"2015-09-22","legal_status":"Granted"} | US9138456B2 Formulation | 22 Sep, 2015 | Granted | 23 Nov, 2030 | |
| {"application_id":"66863","ingredient":"DAPTOMYCIN","trade_name":"DAPTOMYCIN","family_id":"0c1d66c6f4db4df7a43f","publication_number":"US9655946B2","cleaned_patent_number":"9655946","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-09-11","publication_date":"2017-05-23","legal_status":"Granted"} | US9655946B2 Formulation | 23 May, 2017 | Granted | 11 Sep, 2033 | |
| {"application_id":"66842","ingredient":"DAPTOMYCIN","trade_name":"DAPTOMYCIN","family_id":"0c1d66c6f4db4df7a43f","publication_number":"US10357535B2","cleaned_patent_number":"10357535","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-09-11","publication_date":"2019-07-23","legal_status":"Granted"} | US10357535B2 Formulation | 23 Jul, 2019 | Granted | 11 Sep, 2033 | |
| {"application_id":"130700","ingredient":"DAPTOMYCIN","trade_name":"DAPTOMYCIN","family_id":"","publication_number":"US12053502B2","cleaned_patent_number":"12053502","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-08-28","publication_date":"2024-08-06","legal_status":"Granted"} | US12053502B2 | 06 Aug, 2024 | Granted | 28 Aug, 2038 | |
| {"application_id":"115292","ingredient":"DAPTOMYCIN","trade_name":"DAPTOMYCIN","family_id":"f5f156023268468ea734","publication_number":"US11759497B2","cleaned_patent_number":"11759497","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-08-28","publication_date":"2023-09-19","legal_status":"Granted"} | US11759497B2 Formulation | 19 Sep, 2023 | Granted | 28 Aug, 2038 | |
| {"application_id":"66871","ingredient":"DAPTOMYCIN","trade_name":"DAPZURA RT","family_id":"cca82ecb7b1b4225a400","publication_number":"US11173189B2","cleaned_patent_number":"11173189","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-03-11","publication_date":"2021-11-16","legal_status":"Granted"} | US11173189B2 Formulation | 16 Nov, 2021 | Granted | 11 Mar, 2041 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Daptomycin
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.